Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease

Tapan Dey, Jatin Kalita , Sinead Weldon, Clifford C. Taggart

Research output: Contribution to journalArticlepeer-review

252 Downloads (Pure)


In the context of respiratory disease, chronic obstructive pulmonary disease (COPD) is the leading cause of mortality worldwide. Despite much development in the area of drug development, currently there are no effective medicines available for the treatment of this disease. An imbalance in the protease: Antiprotease ratio in the COPD lung remains an important aspect of COPD pathophysiology and several studies have shown the efficacy of antiprotease therapy in both in vitro and in vivo COPD models. However more in-depth studies will be required to validate the efficacy of lead drug molecules targeting these proteases. This review discusses the current status of protease-directed drugs used for treating COPD and explores the future prospects of utilizing the potential of antiprotease-based therapeutics as a treatment for this disease
Original languageEnglish
Article number244
JournalJournal of Clinical Medicine
Issue number9
Publication statusPublished - 28 Aug 2018


Dive into the research topics of 'Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease'. Together they form a unique fingerprint.

Cite this